AstraZeneca announced Phase I trial data for its PCSK9 inhibitor, AZD0708. AZD0780 is an oral small molecule PCSK9 inhibitor as a first-in-class therapy for patients with dyslipidemia that cannot be controlled by statins alone. PSCK9 is a well-known and validated target in lipid metabolism and inhibiting PSCK9 signalling has shown to be effective in reducing LDL cholesterol levels in plasma. Lower LDL-C levels are associated with a reduction in the risk of long-term cardiovascular disease and major cardiovascular events.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.